Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
DermatologyResearch Phase

Trylagen (Tripeptide-10 Complex)

Topical
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Trylagen is a proprietary complex incorporating Tripeptide-10 Citrulline along with additional bioactive peptides formulated to support collagen and elastin network architecture. The complex aims to influence multiple stages of extracellular matrix synthesis and assembly, including fibroblast proliferation, procollagen processing, and elastin fiber organization.

Mechanism of Action

The therapeutic rationale is directed toward comprehensive photoaging correction and improvement of skin firmness.

Research Summary & Key Findings

Preclinical studies have reported increased expression of collagen I, collagen III, and fibrillin in fibroblast cultures and organotypic skin models. Published clinical trial evidence in indexed dermatology journals remains sparse, with available data largely derived from manufacturer-led assessments of skin elasticity and wrinkling.

Clinical Status

Research Phase

Trylagen (Tripeptide-10 Complex) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Dermatology

No lawful pathway today

Trylagen (Tripeptide-10 Complex) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.